ZURICH (Reuters): Swiss pharmaceutical group Roche said on Monday that it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.
Under terms of agreement, which provides Roche with exclusive commercialisation rights outside of the United States and joint commercialisation rights within the country, Alnylam would receive an upfront payment of $310 million, Roche said.
ISLAMABAD (INP): An International Monetary Fund (IMF) mission has reached the Finance Ministry to commence…
F.P. Report HYDERABAD: Sindh Senior Minister and Provincial Minister for Information, Transport and Mass Transit,…
Humayun Khan PESHAWAR: Peshawar High Court (PHC) Justice Ijaz Anwar annoyed police role and observed…
F.P. Report PESHAWAR: An important meeting was held on Monday with Chief Minister Khyber Pakhtunkhwa…
F.P. Report PESHAWAR: The opposition leader in Khyber Pakhtunkhwa Assembly, Dr. Ibadullah, while starting debate…
This website uses cookies.